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Although tissue uptake of fatty acids from chylomicrons is primarily via lipoprotein lipase (LpL) hydrolysis of triglycerides
(TGs), studies of patients with genetic LpL deficiency suggest additional pathways deliver dietary lipids to tissues. Despite
an intact endothelial cell (EC) barrier, hyperchylomicronemic patients accumulate chylomicron-derived lipids within skin
macrophages, leading to the clinical finding eruptive xanthomas. We explored whether an LpL-independent pathway
exists for transfer of circulating lipids across the EC barrier. We found that LpL-deficient mice had a marked increase in
aortic EC lipid droplets before and after a fat gavage. Cultured ECs internalized chylomicrons, which were hydrolyzed
within lysosomes. The products of this hydrolysis fueled lipid droplet biogenesis in ECs and triggered lipid accumulation in
cocultured macrophages. EC chylomicron uptake was inhibited by competition with HDL and knockdown of the scavenger
receptor-BI (SR-BI). In vivo, SR-BI knockdown reduced TG accumulation in aortic ECs and skin macrophages of LpL-
deficient mice. Thus, ECs internalize chylomicrons, metabolize them in lysosomes, and either store or release their lipids.
This latter process may allow accumulation of TGs within skin macrophages and illustrates a pathway that might be
responsible for creation of eruptive xanthomas.
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Introduction
The delivery of dietary lipids for metabolic use in peripheral 
tissues is a fundamental biological process in all vertebrates. In 
mammals, these lipids circulate mostly as components of lipo-
proteins in the form of phospholipids (PLs), triglycerides (TGs), 
and cholesteryl esters (CEs). For tissues without fenestrated 
capillaries, lipid uptake requires the passage of lipoproteins or 
their components across the endothelial barrier (1). However, 
despite the importance of this process in whole-body metabo-
lism and homeostasis, how lipids cross the endothelium is still 
not fully understood.
Due to their relevance in the physiopathology of athero-
sclerosis, endothelial uptake and transcytosis of cholesterol- 
carrying lipoproteins LDL and HDL have been extensively 
studied, and a series of receptors have recently been implicated 
in this process (reviewed in ref. 2). In contrast, most lipid deliv-
ery from larger TG-rich lipoproteins (TRLs) VLDL and chylo-
microns does not appear to involve transcytosis and uptake 
of whole lipoproteins. The canonical pathway for delivery of 
TRL-derived lipids to parenchymal tissues involves lipolysis at 
the capillary surface by lipoprotein lipase (LpL) and, at low fatty 
acid (FA) concentrations, FA transporter proteins, such as clus-
ter of differentiation 36 (CD36) (3–6). LpL is synthesized in the 
parenchyma of metabolically active tissues, such as heart, skel-
etal muscle, and adipose (7, 8), and is anchored to endothelial 
cells (ECs) at the luminal surface of the capillary via its interac-
tion with glycosylphosphatidylinositol-anchored HDL-binding 
protein 1 (GPIHBP1) (9). There, LpL mediates the lipolysis of 
TGs, allowing released FAs to be taken up into parenchymal 
cells. However, clinical and experimental evidence indicate 
that additional pathways independent of LpL must mediate the 
uptake of TRL-derived lipids.
Patients with genetic loss of LpL, its obligate binding GPI-
HBP1, its coactivator apoC2, or lipase maturation factor 1 (LMF1) 
exhibit defective TRL lipolysis, fasting hyperchylomicronemia, 
and recurrent pancreatitis (10–13). Fasting hyperchylomicronemia 
is a rare disorder, and its relationship to cardiovascular disease 
(CVD) is unclear (14–16). Also unclear is why these patients, who 
have a major defect in lipid metabolism, do not exhibit defec-
tive adipose development or impaired heart or skeletal muscle 
mechanics. In contrast with patients who have defective produc-
tion of chylomicrons due to defects in either apoB or microsomal 
TG transfer protein (17), LpL-deficient patients do not exhibit 
visual, neurological, immunological, or coagulation defects due to 
fat-soluble vitamin deficiency.
LpL-deficient patients develop cutaneous eruptive xantho-
mas, papular lesions characterized by the accumulation of lipid- 
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We have previously shown that mice with endothelial-specific 
knockout of CD36 exhibit impaired uptake of long-chain FAs into 
heart, skeletal muscle, and brown adipose tissue as well as elevated 
postprandial TG levels (4). To assess whether CD36-mediated 
endothelial FA uptake is required for postprandial LD biogenesis 
in aortic ECs, we administered an olive oil gavage to EC-Cd36–/– 
and EC-Cd36fl/fl mice and monitored plasma TG and aortic EC LD 
content over time. As in LpL-deficient mice, both postprandial TG 
and LD content within aortic ECs were increased in EC-Cd36–/– 
mice as compared with floxed controls (Figure 1D). Plasma TG 
levels and LDs per cell are shown in Figure 1, E and F.
Next, we assessed LD formation in cultured ECs exposed to puri-
fied TRLs. Immediately following a fat load, TGs circulate mostly 
as components of chylomicrons (23). Therefore, mouse ECs 
(MECs) were deprived of serum overnight to ensure minimal LD 
content and then exposed to purified human chylomicrons (4mg/
dL TG) in FBS-free medium for 120 minutes. Cells were immu-
nostained for LD coat protein perilipin 2 in addition to BODIPY 
493/503. MECs deprived of serum overnight exhibited only 
background signal of both perilipin 2 (red) and BODIPY 493/503 
(green), indicating LD depletion (Figure 1G). In the absence of LpL 
or any other lipid source, MECs exposed to chylomicrons formed 
LDs, assessed by the presence of perilipin 2/BODIPY 493/503–
positive puncta (Figure 1H). Pretreatment with 10 U/mL LpL with 
or without heparin enhanced accumulation of LDs (Figure 1, I and 
J), which were significantly larger than those arising from incu-
bation with chylomicrons alone (quantified in Figure 1K). In this 
setting, LD size strongly correlated with the concentration of FAs 
in the media after treatment, which was increased in cells pre-
treated with LpL (Figure 1, L and M).
These observations suggest that, although LpL-hydrolyzed 
chylomicron FAs may contribute to postprandial LD biogenesis in 
ECs, tissues with little or no LpL expression are likely to have other 
lipid-uptake mechanisms.
ECs exposed to purified chylomicrons exhibit 2 populations of 
TG-rich droplets. To further characterize the nature of postpran-
dial endothelial LDs, we exposed aortas from WT mice to puri-
fied human chylomicrons ex vivo. LDs were visible within ECs of 
VE-cadherin– and BODIPY 493/503–stained aortas after a 30- or 
120-minute exposure to chylomicrons (Figure 2A). Particle-size 
analysis of intracellular BODIPY 493/503–positive structures 
evidenced that endothelial LDs were significantly larger at longer 
incubations, and similar results were obtained in cultured MECs 
exposed to chylomicrons in vitro (Figure 2B). In both settings, 
LD size more than doubled at 120-minute relative to 30-minute 
incubations (Figure 2C).
MECs exposed to chylomicrons for 120 minutes exhibited 
large (average size, ~250 nm) BODIPY 493/503–positive droplets 
(green) which colocalized with perilipin 2 (red) (Figure 2, D and E). 
However, there was no detectable perilipin 2 signal or colocaliza-
tion with small (average size, ~100 nm) BODIPY 493/503–positive 
puncta at short (30 minutes) incubation times (Figure 2, D and E).
Each chylomicron carries 1 molecule of apoB48, the amino ter-
minal 48% of apoB100, which is produced from the APOB gene in 
the intestine by an mRNA-editing process (24). To assess whether 
the smaller (~100 nm, Figure 2D) BODIPY 493/503–positive 
structures represented internalized chylomicrons, we exposed 
laden macrophages in the skin (18). The biological process 
underlying this pathological sign remains poorly understood. 
Eruptive xanthomas are overlaid by an intact endothelium, 
which would preclude the paracellular passage of unhydrolyzed 
TLRs. However, lipids within xanthoma skin macrophages are 
strikingly similar to those carried by circulating chylomicrons 
(19), suggesting that chylomicron lipids cross the endothelial 
barrier in the absence of LpL-mediated lipolysis. Together, 
these clinical observations suggest that a non-LpL pathway for 
delivery of dietary lipids must be operative. In support of this 
hypothesis, Kuo et al. reported that mouse aortic ECs accumu-
late lipid droplets (LDs) in the postprandial period, when levels 
of circulating chylomicrons are elevated (20). In WT mice, these 
LDs could have been generated from lipolysis-derived FAs, 
followed by intracellular reassembly of TG, internalization of 
nonlipolyzed chylomicrons, or a combination of these 2 events. 
Aortic ECs are not surrounded by high LpL-expressing cells, and 
very few cells express GPIHBP1 (21, 22). Therefore, LpL lipoly-
sis products are unlikely to be the primary substrate for aortic 
endothelial LD biogenesis.
Here, we provide evidence that postprandial LD accumulation 
in aortic ECs is independent of LpL activity and requires EC uptake 
of unhydrolyzed chylomicrons via scavenger receptor-BI (SR-BI), 
followed by chylomicron hydrolysis within lysosomes. To illustrate 
this LpL-independent pathway, we assessed TG accumulation in 
skin macrophages, a model for the development of eruptive xantho-
mas. We show that conditioned medium from chylomicron-treated 
ECs induces LD biogenesis in cocultured macrophages and that 
knockdown of SR-BI decreases TG accumulation within skin mac-
rophages of hyperchylomicronemic mice. Our results imply that 
uptake of chylomicrons by ECs may be an important and under-
appreciated pathway for the delivery of circulating TRL-derived 
lipids that is exclusive of intravascular lipolysis.
Results
Postprandial aortic LDs are not lipolysis derived. To determine 
whether postprandial LD biogenesis within aortic ECs requires 
LpL lipolysis, we monitored LD occurrence over time (270 
minutes) following olive oil gavage in control and inducible 
LpL-knockout (iLpl–/–) mice (Figure 1A). Aortas harvested at the 
indicated times were immunostained for endothelial-specific 
membrane protein VE-cadherin (red), and LDs were stained 
with neutral lipid dye 4,4-difluoro-1,3,5,7,8-pentamethyl-4- 
bora-3a,4a-diaza-s-indacene (BODIPY 493/503) (green) for con-
focal microscopy visualization and analysis. Manufacturer and 
catalogue number information for reagents used in this study can 
be found in Supplemental Table 1; supplemental material available 
online with this article; https://doi.org/10.1172/JCI145800DS1. 
Immunostaining for LD coat protein perilipin 2 is shown in Sup-
plemental Figure 1. Aortas from iLpl–/– mice accumulated more 
LDs within aortic ECs. As opposed what occurred in control mice, 
LDs were found prior to the gavage (Figure 1A). As expected, LpL 
deficiency resulted in significantly elevated postprandial TG levels 
(Figure 1B). With increased TG levels, the number of LDs within 
aortic ECs markedly increased, so that by 270 minutes, iLpl–/– mice 
had approximately 4 fold more LDs than Lplfl /fl controls (Figure 1, 
A and B; quantified in Figure 1C).
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Figure 1. Mouse aortic ECs accumulate LDs after an olive oil gavage in the absence of LpL or endothelial CD36. Three- to four-month-old male iLplfl/fl,  
iLpl–/–, EC-Cd36fl/fl, and EC-Cd36–/– mice were fasted for 16 hours and given olive oil by oral gavage (10 ml/kg). Plasma TG and aortic EC LD content were 
assessed at the indicated times (n = 5–8 mice/group/time point). (A–C) Both iLplfl/fl and iLpl–/– mice exhibited BODIPY 493/503–positive (green) LDs within 
aortic ECs, as visualized by confocal microscopy imaging of V-cadherin–immunostained (red) samples (A). Unlike floxed controls, iLpl–/– mice exhibited 
LDs within aortic ECs prior to the olive oil gavage (A, left panels). In the absence of LpL lipolysis, plasma TG (B) and LD accumulation (C) were significantly 
increased. (D–F) EC-specific CD36 deletion resulted in an increase in aortic EC LD content (D, quantified in F), which was mirrored by elevated plasma TG 
levels (E). All comparisons are with flox/flox controls. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, 2-way ANOVA. (G–M) MECs were deprived of 
serum overnight to ensure LD depletion (G) and pretreated with LpL (10 U/ml) (I) or LpL+ heparin (10 U/ml). (J) or maintained in FBS-free medium (H) for 1 
hour before a 120-minute incubation with human chylomicrons. Samples were immunostained with LD marker perilipin 2 (red) and stained with BODIPY 
493/503 (green). LDs were significantly larger in the presence of LpL+/– heparin pretreatment (K), and their size correlated with the presence of FFAs in 
the media after treatment (M), which was significantly increased in samples pretreated with LpL+/– heparin (L). Data are represented as mean ± SEM of 
7 independent experiments. **P < 0.01; ***P < 0.001; ****P < 0.0001, 1-way ANOVA, Dunnet’s multiple comparisons test. Scale bars: 10 μm. Additional 
inset magnification, ×2.5.
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or LD biogenesis, it resulted in a significant increase of LD size 
(Figure 3J), in keeping with reports that ATGL is required for LD 
mobilization in ECs (20).
Endocytosis inhibitor dynasore blocks EC chylomicron uptake. 
Several receptors are involved in the recognition, binding, and 
uptake of chylomicron remnants (CMRs) by the liver. LDL recep-
tor (LDLR) and LDLR-related protein/α2-macroglobulin receptor 
(LRP) recognize CMRs in an apoE-dependent manner following 
lipolysis by LpL (36, 37). SR-BI, as well as heparan sulfate proteo-
glycans, may be involved in the “capture step” that precedes the 
LDLR and LRP-mediated endocytosis of CMR in hepatocytes 
(38). Additionally, macrophages in culture have been reported to 
internalize and degrade chylomicrons in an apoC-II and macro-
phage derived LpL-dependent manner (39). However, no recep-
tor has been reported to participate in the uptake of unhydrolyzed 
chylomicrons. As a first approach to assess the endothelial chy-
lomicron uptake route, we pulsed serum-deprived MECs with 
chylomicrons in the absence or presence of dynasore to inhibit 
endocytic uptake (40, 41). Treatment with dynasore blocked 
chylomicron internalization, leading to their accumulation at the 
plasma membrane of MECs (Figure 4A).
We next aimed to identify the site of chylomicron membrane 
binding. Binding of CMRs to heparan sulfate proteoglycans in 
hepatocyte membranes mediates 1 route of uptake (42, 43), a pro-
cess that is abrogated by heparin (44). Treatment with heparin (5 
U/mL) had no effect on MEC chylomicron uptake in culture (Sup-
plemental Figure 4), suggesting that binding of chylomicrons to 
the surface of MECs could be directly through a receptor.
Endothelial lipase (EL) has been shown to provide an alter-
native pathway for the uptake of lipoprotein-derived FAs into the 
adipose tissue of LpL-deficient mice (45) as well as to participate 
in the binding and cellular uptake of LDL and HDL particles (46). 
The lack of effect of heparin treatment, which releases EL from 
the EC surface (45), suggested that EL was not involved in the 
uptake of chylomicrons. To further confirm this, we used siRNA 
to specifically knock down EL. As shown in Supplemental Figure 
5, knockdown of EL had no effect on the uptake of fluorescence- 
labeled (labeled with 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindo-
carbocyanine perchlorate [DiI]) chylomicrons (shown in red).
EC chylomicron uptake is independent of LDLR and ALK1. The 
process of endothelial chylomicron uptake and degradation out-
lined so far is reminiscent of the LDLR-mediated endocytosis 
and lysosomal delivery of LDL. The apoB100 in LDL particles is 
recognized by LDLR, promoting LDL uptake into the cells. The 
internalized particles are routed to endosomes, where LDL dis-
sociates from LDLR and is transferred to lysosomes for further 
degradation. Inhibition of the lysosomes with chloroquine (47) or 
with BafA1 (48) blocks LDL degradation. Further, LDL uptake in 
cultured cells is suppressed by inhibiting endocytosis with 80 μM 
dynasore (49, 50). Chylomicrons lack the LDLR binding sequence 
of apoB, which is located in the C-terminal half of the full-length 
protein. However, LDLR also exhibits high affinity for apoE, 
which is present in both chylomicrons and their remnants. To 
assess whether LDLR was required for chylomicron uptake in ECs, 
we administered DiI-labeled chylomicrons (shown in red) retroor-
bitally to Ldlr–/– mice and WT controls. Plasma TG was monitored 
15 minutes after injection, and thoracic aortas were harvested to 
cultured MECs to purified chylomicrons for 30 or 120 minutes 
and immunostained for apoB. Similar levels of intracellular apoB- 
positive puncta were detected following 30- or 120-minute incu-
bations with chylomicrons (Figure 2F). At 30 minutes, apoB fully 
colocalized with BODIPY 493/503–positive puncta (Figure 2G). 
However, colocalization at 120 minutes was partial, observed only 
in the population of smaller BODIPY 493/503–positive structures 
(Figure 2H). These data suggest that at 120-minute incubation, 
newly biosynthesized LDs coexist with internalized chylomicrons 
within ECs. Chylomicrons obtained from iLpl–/– mice, as well as 
from an LpL-deficient patient, were also tested and yielded sim-
ilar results (Supplemental Figure 2, A and B).
Intracellular apoB signal disappears over time. ECs exposed to 
chylomicrons in culture formed LDs in the absence of LpL lip-
olysis or any other lipid source. In addition, intracellular apoB- 
positive/BODIPY 493/503 puncta were visible early with chy-
lomicron exposure while apoB-negative/perilipin 2–positive/
BODIPY 493/503 LDs only appeared at longer incubation times. 
These observations suggested that internalized chylomicrons 
provide the substrate for LD biogenesis in ECs. To assess this, we 
first monitored apoB and BODIPY 493/503 signals over time in 
MEC pulsed with human chylomicrons for 30 minutes and then 
switched to FBS-free culture medium for 120 minutes. Approxi-
mately 80% of MEC exhibited approximately 100 nm intracel-
lular apoB/ BODIPY 493/503–positive puncta after a pulse with 
chylomicrons (Figure 3A). The apoB signal rapidly declined when 
MECs were switched to FBS-free medium (Figure 3B and quanti-
fication in Figure 3C; time course in Supplemental Figure 3A), but 
the number of cells still exhibiting cytoplasmic BODIPY 493/503–
positive puncta did not change (Figure 3D). However, the LD at 
120 minutes were significantly larger (~300 nm; Figure 3E) and 
did not colocalize with apoB (as shown in Figure 3B).
LD biogenesis in ECs requires chylomicron hydrolysis in lyso-
somes. De novo LD biogenesis in eukaryotic cells occurs in the 
endoplasmic reticulum, typically in response to excess intracellu-
lar FAs (25–28). To determine whether intracellular chylomicron 
hydrolysis was the source of FAs for LD biogenesis in MECs, we 
studied the effect of 2 specific inhibitors on intracellular chylo-
micron clearance and LD appearance. Atglistatin is a selective 
inhibitor of adipose TG lipase (ATGL), the rate-limiting enzyme 
involved in the mobilization of FAs from intracellular TG stores 
(29–32). Bafilomycin A1 (BafA1), commonly used to inhibit lyso-
somal degradation, selectively inhibits the vacuolar-type H+-AT-
Pase (V-ATPase) (33), preventing acidification of organelles and 
activation of lysosome lipase (34, 35). As expected, MECs pulsed 
with chylomicrons for 30 minutes exhibited intracellular apoB/
BODIPY 493/503 puncta (white merge of magenta and green) 
(Figure 3F), and apoB staining was lost when cells were switched 
to FBS-free medium for 120 minutes (Figure 3G). Inhibition of 
ATGL did not block degradation of intracellular chylomicrons, as 
monitored by loss of cytoplasmic apoB/BODIPY 493/503 puncta, 
nor appearance of large LDs 120 minutes after a chylomicron 
pulse (Figure 3H). Conversely, inhibition of the lysosomal pro-
ton pump with BafA1 resulted in the retention of apoB/ BODIPY 
493/503–positive puncta throughout the experiment (Figure 3I). 
Importantly, MECs treated with BafA1 did not develop large LDs. 
Although ATGL inhibition did not block chylomicron degradation 
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Figure 2. EC BODIPY493/503–positive droplets become larger over time. (A–E) Aortas obtained from fasted WT mice (A) or serum-deprived cultured 
MECs (B) were incubated with human chylomicrons (4 mg/dL TG in FBS-free medium) for 30 or 120 minutes. Analysis of BODIPY 493/503–positive puncta 
size (>1000 particles/group) showed a significant increase in particle size over time, with average size increasing more than 2-fold both ex vivo and in vitro 
(C). Data are represented as mean ± SEM of 4 (ex vivo) or 12 (in vitro) independent experiments. **P < 0.01; ****P < 0.0001, Student’s t test. (D and E) 
MECs were deprived of serum overnight to ensure LD depletion, then incubated with human chylomicrons (4 mg/dL TG) for the indicated times. (D) Aver-
age size of BODIPY 493/503–positive puncta after 30 minutes (~100 nm) or 120 minutes (~250 nm) exposure to chylomicrons. n = 12 independent exper-
iments. ****P < 0.0001, Student’s t test. (E) Immunostaining for perilipin 2 (red). At 120 minutes, BODIPY 493/503–positive droplets (green) colocalized 
with perilipin 2 (lower panels, colocalization in yellow). There was no perilipin 2 signal or colocalization with BODIPY 493/503–positive droplets at shorter 
(30 minutes) incubations (upper panels). Scale bars: 5 μm. (F–H) Immunostaining for lipoprotein marker apoB. MECs incubated with chylomicrons for 30 or 
120 minutes exhibited similar numbers of intracellular apoB-positive puncta (F). At 30-minute incubation, BODIPY 493/503–positive puncta (green) fully 
colocalized with apoB (magenta, G). Colocalization at 120 minutes was partial, with only smaller BODIPY 493/503–positive puncta colocalizing with apoB 
(H). White arrows indicate apoB/BODIPY 493/503–positive puncta. Scale bars: 10 μm. Additional inset magnification, ×2.5.
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assess DiI-chylomicron content within aortic ECs. Both Ldlr–/– and 
WT mice exhibited a significant increase in plasma TG levels 15 
minutes after the administration of DiI-chylomicrons (Supple-
mental Figure 6A). Confocal microscopy analysis revealed no sig-
nificant difference in DiI-chylomicron content within aortic ECs 
of WT and LDLR-deficient mice (Supplemental Figure 6B), sug-
gesting that EC chylomicron uptake is independent of LDLR. We 
then exposed MECs in culture to DiI-chylomicrons in the absence 
Figure 3. Intracellular chylomicron hydrolysis at the lysosomal compartment precedes LD biogenesis in ECs. (A–E) Cultured MECs were deprived of 
serum overnight and exposed to human chylomicrons (4 mg/dL in FBS-free medium). After a 30-minute pulse, cells were either fixed (0 minutes) or 
maintained in FBS-free medium for 120 minutes. (A) As expected, cells fixed immediately after the chylomicron pulse exhibited intracellular apoB/
BODIPY 493/503–positive puncta (average size, ~100 nm, E). (B) Incubation for 120 minutes in FBS-free medium after pulse resulted in loss of intra-
cellular apoB signal (quantified in C), accompanied by the appearance of larger, BODIPY 493/503–positive puncta (average size ~ 300 nm, E). Data 
are represented as mean ± SEM of 8 independent experiments. ****P < 0.0001, Student’s t test. (F–I) MECs were pulsed for 30 minutes with human 
chylomicrons, then fixed (F) or switched for 120 minutes to FBS-free medium alone (G) or in the presence of ATGL inhibitor atglistatin (H) or lysosomal 
proton pump inhibitor BafA1. (I). Average BODIPY 493/503–positive particle size (n = 7 independent experiments) is represented in J. Inhibition of ATGL 
did not preclude chylomicron degradation as monitored by loss of intracellular apoB signal nor the appearance of large (~300 nm) LDs. Conversely, inhi-
bition of lysosomal hydrolysis with BafA1 resulted in the retention of apoB/BODIPY 493/503–positivecytoplasmic puncta (~100 nm) for the duration of 
the treatment. Data are represented as mean ± SD. ***P < 0.001; ****P < 0.0001, 1-way ANOVA, Dunnet’s multiple comparisons test. Scale bars: 10 μm. 
Additional inset magnification, ×2.
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or presence of apoB18, a peptide comprising the 18% NH2-termi-
nal sequence of apoB100 (51) that lacks the LDLR-binding site. 
Coincubation with apoB18 resulted in dose-dependent inhibi-
tion of DiI-chylomicron uptake (Figure 4B), suggesting that the 
NH2-terminus of apoB is involved in the process.
A recent genome-wide iRNA screen revealed that activin 
receptor-like kinase 1 (ALK1) mediates LDL uptake and transcy-
tosis in ECs (52). Downregulation of ALK1 in cultured ECs inhib-
ited uptake of apoB100-carrying lipoproteins LDL and VLDL, but 
not of apoA-I–rich HDL. Competition with LDLR did not inhibit 
the binding of ALK1 to LDL, suggesting that LDL-ALK1 interac-
tion was not via the LDLR-binding region of apoB (52). However, 
downregulation of ALK1 with siRNA had no effect on DiI-chylomi-
cron uptake (Figure 4C).
Knockdown of SR-BI inhibits chylomicron uptake in ECs. SR-BI 
is a type 1 integral membrane protein that can interact with a 
variety of lipoproteins via its extracellular loop (53, 54). SR-BI 
is abundantly expressed in most ECs, and it plays a central role 
in the metabolism and endothelial transcytosis of its canoni-
cal ligand HDL (55, 56). Recent studies have demonstrated that 
SR-BI also mediates EC uptake and transcytosis of LDL in a pro-
cess that is inhibited by competition for the receptor with HDL 
(57, 58). Our competition studies showed that uptake of both DiI- 
chylomicrons and DiI-LDL by MECs was significantly inhibited 
by coincubation with unlabeled HDL (Figure 4D and Supplemen-
tal Figure 7A), while unlabeled LDL or VLDL had no effect on DiI- 
chylomicron uptake (Supplemental Figure 7, B and C). Togeth-
er, these observations suggested the involvement of a receptor 
for HDL. We next treated MECs with antisense oligonucleotides 
(ASOs), which inhibited SR-BI expression in cultured MECs (Sup-
plemental Figure 8A). The SR-BI ASOs significantly inhibited the 
uptake of DiI-labeled chylomicrons by MECs (Figure 4E).
We then assessed whether inhibiting SR-BI in vivo affected 
chylomicron uptake in aortic ECs. WT mice injected with SR-BI 
ASO (100 mg/kg, once a week for 3 weeks) exhibited strong sys-
temic downregulation of SR-BI (Figure 5A), which was apparent 
in both aorta (Figure 5B) and aortic ECs immunostained for SR-BI 
(green; Figure 5, C and D). Despite the high level of similarity 
between SR-BI and CD36, this ASO did not reduce CD36 expres-
sion (Supplemental Figure 8B). Following SR-BI knockdown, 
DiI-labeled chylomicrons were administered retroorbitally and 
their uptake into aortic ECs assessed by confocal microscopy 
imaging of aortas harvested 15 minutes after injection. SR-BI 
knockdown induced fasting hypertriglyceridemia (Figure 5E). 
Circulating TG levels increased further in SR-BI–deficient mice 
and also increased in control mice 15 minutes after DiI-chylomi-
cron administration (Figure 5F). SR-BI inhibition significantly 
blocked DiI-chylomicron uptake by aortic ECs in vivo, as com-
pared with that in mice treated with control ASO (Figure 5G).
Downregulation of SR-BI in iLpl–/– mice reduces LD accumulation 
in aortic ECs. Our initial observations in iLpl–/– mice strongly sug-
gested that postprandial LD biogenesis in aortic ECs is not strictly 
dependent on LpL-mediated hydrolysis of TRLs. To determine 
whether SR-BI–mediated uptake of chylomicrons was a source 
of lipids for this process, we knocked down SR-BI in iLpl–/– mice 
(Figure 5H) before administration of an oral olive oil gavage. 
iLpl–/– mice treated with control ASO or SR-BI ASO exhibited sim-
ilarly elevated TG levels (Figure 5I). As expected, EC LDs were 
markedly increased in aortic ECs from iLpl–/– mice (Figure 5, J 
and K) 180 minutes after gavage, as compared with floxed con-
trols. Knockdown of SR-BI in an LpL-knockout context reduced 
LD accumulation in aortic ECs to a level similar to that of Lplfl/fl 
controls (Figure 5, J and K).
Together, our data support a model whereby chylomicrons are 
internalized by ECs via SR-BI and are subsequently hydrolyzed 
within lysosomes. The products of intracellular chylomicron deg-
radation fuel LD formation in ECs.
SR-BI–mediated endothelial chylomicron uptake and metabo-
lism trigger LD formation in cocultured primary peritoneal macro-
phages. Patients with familial LpL deficiency exhibit impaired TG 
lipolysis and fasting hyperchylomicronemia, which can lead to 
the appearance of eruptive xanthomas (18). A 1970 study pro-
vided evidence for the chylomicron origin of lipids within mac-
rophages of diabetic eruptive xanthomas (19). However, the 
authors did not observe chylomicrons within ECs nor did they 
find a disruption of the EC barrier. We postulated that visualiza-
tion of chylomicrons within ECs would be difficult due to their 
rapid movement and metabolism. Our results in cultured MECs 
have shown that intracellular chylomicron degradation occurs 
rapidly, as monitored by loss of cytoplasmic apoB puncta upon 
removal of chylomicron-containing media (Figure 3, A and B, and 
Supplemental Figure 3A). In WT mice, chylomicrons were visible 
within ECs of aortas harvested 15 minutes after DiI-chylomicron 
intravenous administration. Consistent with our in vitro results, 
DiI-chylomicron signal declined rapidly when newly harvested 
aortas were maintained in FBS-free medium for 2 to 30 minutes 
before fixing; an approximately 50% reduction occurred within 
the first 2 minutes (Supplemental Figure 3B).
We hypothesized that SR-BI–mediated EC chylomicron 
uptake and catabolism could represent a pathway for the delivery 
of chylomicron-derived lipids independent of LpL activity. The 
bell-shaped distribution of LD occurrence in aortic ECs is con-
sistent with a dynamic process of LD biogenesis and catabolism 
in response to postprandial plasma TG levels (Figure 1, A–F). LD 
hydrolysis in cultured ECs has been reported to result in the release 
of FAs into the medium, which can be internalized and reesterified 
by cocultured skeletal muscle cells (20). As a first step to address 
this hypothesis, we assessed LD formation in primary peritoneal 
macrophages (PMACs) cocultured with MECs. Figure 6A shows a 
graphic depiction of the experimental design. PMACs cocultured 
with MECs exposed to a chylomicron pulse contained significantly 
more LDs than those cocultured with untreated MECs (Figure 
6B, quantification in Figure 6C). This effect was abrogated when 
MECs were treated with lysosomal inhibitor BafA1 following the 
chylomicron pulse, but not by inhibition of ATGL in chylomi-
cron-laden MECs. Importantly, SR-BI–deficient MECs exposed to 
chylomicrons did not increase LD content in cocultured PMACs. 
These results suggest that endothelial chylomicron uptake and 
hydrolysis result in the release of metabolically active factors 
capable of triggering LD biogenesis in underlying cells.
To our surprise, our colorimetric assays were unable to detect 
an increase of FAs in the media of MECs exposed to a chylomi-
cron pulse. Ultra-performance liquid chromatography coupled 
with quadrupole time-of-flight mass spectrometry (UPLC-TOF-
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Figure 4. Mechanisms of endothe-
lial chylomicron uptake. (A) MEC 
were incubated for 30 minutes 
with human chylomicrons in the 
absence (left panel) or presence of 
the endocytosis inhibitor dynasore 
(80 μM, right panel). Treatment 
with dynasore blocked chylomicron 
uptake, resulting in the accumula-
tion of apoB/BODIPY 493/503– 
positive chylomicrons in the plasma 
membrane. Dashed lines show the 
outline of the cell. (B–E) Cul-
tured ECs were deprived of serum 
overnight, and DiI-labeled human 
chylomicrons (4 mg/dL TG, red) 
were used to monitor uptake after a 
30-minute pulse. (B) Coincubation 
with apoB18 peptide (the NH2- 
terminal sequence of apoB100, 0.4 
or 0.8mg/dL) significantly inhibited 
DiI-chylomicron uptake in MECs. 
Data are represented as mean ± SD 
of 8 independent experiments. All 
comparisons are with control. *P < 
0.05; ***P < 0.001, 1-way ANOVA, 
Dunnet’s multiple comparisons 
test. (C) Cells treated with control 
siRNA or ALK1 siRNA were deprived 
of serum overnight and pulsed for 
30 minutes with DiI-labeled chy-
lomicrons. DiI-chylomicron uptake 
was not significantly reduced in 
ALK1-deficient cells. (D) DiI- 
chylomicron uptake was significant-
ly inhibited by coincubation with 
unlabeled HDL (25 mg/dL choles-
terol). (E) MECs were treated with 
either control or SR-BI ASO for 24 
hours, deprived of serum overnight, 
and pulsed with DiI-chylomicron. 
Knockdown of SR-BI significantly 
inhibited DiI-chylomicron uptake. 
Data are represented as mean ± 
SEM of 4–9 independent experi-
ments. All comparisons are with 
control. *P < 0.05; ****P < 0.0001, 
Student’s t test. Scale bars: 10 μm. 
Additional inset magnification, ×2.
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in aortic ECs from LpL-deficient mice. Together, these results 
strongly support a model of LpL-independent receptor-mediated 
uptake and processing of chylomicron-derived lipids by ECs.
SR-BI, expressed in most ECs, was previously reported to 
mediate transcytosis of HDL and LDL across the EC barrier (57, 
58, 60, 61). We describe an additional role for SR-BI, to mediate 
chylomicron uptake. Although our studies focused on ECs, the 
increased postprandial TG levels in our WT mice treated with ASO 
(Figure 5E) might reflect effects in the liver. Others have reported 
increased TG levels in SR-BI knockout mice as well as delayed chy-
lomicron TG clearance (38). These findings strongly support our 
model whereby SR-BI mediates uptake of unhydrolyzed chylomi-
crons and add to the mounting evidence that SR-BI is a multifunc-
tional player in whole-body lipid metabolism and homeostasis.
SR-BI–mediated endothelial chylomicron uptake and catabolism 
represent a potential pathway for the delivery of dietary TG to under-
lying tissues. The process of endothelial chylomicron uptake and 
intracellular hydrolysis described in this study may result in the 
release by ECs of lipid products for metabolic use in subendothe-
lial parenchymal tissues. This could be relevant to the pathophysi-
ology of disorders associated with LpL deficiency, where chylomi-
cron levels are severely elevated. We have shown that media from 
chylomicron-laden ECs induce LD biogenesis in cocultured mac-
rophages; this process requires endothelial chylomicron hydroly-
sis in lysosomes. ECs with downregulated SR-BI failed to induce 
LD formation in cocultured PMACs. We created a mouse model 
of eruptive xanthomas. LpL-deficient mice exhibited a significant 
(P < 0.0001) increase in LD-containing skin macrophages, which 
was partially reduced by SR-BI downregulation.
Although we have focused on TG movement to skin mac-
rophages, we suspect EC chylomicron uptake and intracellular 
processing in the lysosome delivers lipids to a variety of paren-
chymal tissues. This pathway may explain the normal adipose 
stores in mice and humans with LpL deficiency (62), where some 
lipoatrophy from defective lipid uptake by adipocytes would be 
expected. Consistently, LpL-deficient patients do not develop 
complications of fat-soluble vitamin deficiency, which do occur 
with abetalipoproteinemia (63). Although it is generally believed 
that liver metabolism of retinoids requires uptake of CMRs, and 
conversion of dietary retinyl ester to retinol (64), an alternative 
pathway, as suggested by our studies, likely delivers vitamin A 
to peripheral tissues in LpL-deficient patients. Because we and 
others (20) show that WT mice also exhibit aortic EC LDs in the 
postprandial period (see floxed controls in Figure 1, A and D, and 
Figure 5K), we suspect that this pathway is operative in mice and 
humans who are not LpL deficient.
We should note that the lipid-filled skin macrophages 
found with hyperchylomicronemia should not be equated with 
the cholesteryl-ester–rich foam cells seen in atherosclerosis, as 
cholesterol — but not TG-rich foam cells — are the pathologic 
signature of atherosclerosis. Although occasional cases of ath-
erosclerotic CVD have been described in patients with homozy-
gous LpL deficiency, these are likely to be the exception, as most 
investigators view nascent lipoproteins as nonatherogenic. 
This contrasts with partially digested or remnants of lipopro-
teins, which are atherogenic and a likely reason for greater CVD 
risk with heterozygous LpL deficiency.
MS) analysis confirmed that FA concentration in the conditioned 
media of chylomicron-pulsed MECs was variable but low (0.14 
mM ± 0.12) and did not differ from that of untreated MECs. Fur-
ther research will be required to characterize the lipids released 
by ECs following intracellular chylomicron hydrolysis as well as 
the mechanisms regulating their uptake by macrophages. PMACs 
from CD36-deleted mice accumulated LDs when cocultured with 
chylomicron-laden MECs (Supplemental Figure 9), suggesting 
that CD36 is not a key transporter in this process.
Downregulation of SR-BI reduces LD accumulation in skin mac-
rophages of LpL-deficient mice. Finally, to assess whether SR-BI–
mediated endothelial chylomicron uptake is a physiologically rel-
evant source for chylomicron-derived lipids in an LpL-deficiency 
context, we assessed LD content in skin macrophages from iLpl–/– 
mice treated with either control or SR-BI ASO. Confocal micros-
copy images of skin samples from 6 mice per group (as well as 
from 6 nonhypertriglyceridemic Lplfl/fl controls) immunostained 
for CD68 (red) and stained with BODIPY 493/503 (green) to 
label LDs are shown in Figure 6, D and E. Approximately 45% 
of skin macrophages from iLpl–/– mice contained LDs, more than 
double that of floxed controls. Knockdown of SR-BI in iLpl–/– 
mice partially rescued this phenotype, resulting in a significant 
(P < 0.0001) reduction of the percentage of LD-positive macro-
phages in LpL-deficient animals.
Discussion
The distribution of chylomicron-derived lipids into parenchymal 
tissues has been extensively studied and largely linked to tissue 
expression and activity of LpL (59). The major route of uptake of 
chylomicron-derived FAs requires lipolysis and dissociation of 
nonesterified FAs (NEFA) from the apoB-containing remnant. 
However, an increasing body of clinical and experimental evi-
dence suggests the existence of alternative pathways for endothe-
lial chylomicron-derived lipid uptake independent of LpL activity.
We show that receptor-mediated uptake and lysosomal pro-
cessing of chylomicrons might contribute to lipid accumulation in 
subendothelial macrophages. We used LpL deficiency as a model 
for studying movement of chylomicrons into ECs and to illustrate 
how chylomicrons not metabolized in the circulation can supply 
lipids to skin macrophages, as occurs with eruptive xanthomas. 
The pathway we describe illustrates a process likely to occur in 
LpL-deficient sites, such as in large blood vessels lined by ECs that 
do not express GPIHBP1 (9) and in the setting of LpL deficiency.
Internalized chylomicrons fuel LD biogenesis in ECs. In the pres-
ent study, we show that LpL hydrolysis of chylomicron TG is not 
required for postprandial LD formation in mouse aortic ECs. 
LpL-deficient mice exhibited a marked increase in aortic endothe-
lial LD content after an olive oil gavage, when chylomicron levels 
were severely elevated. Our in vitro studies showed that ECs inter-
nalize intact chylomicrons and that their intracellular hydrolysis at 
the lysosomal compartment fuels endothelial LD biogenesis.
Chylomicrons associate with and are internalized by ECs. This 
process seems to require the NH2 terminus of apoB and is inhibited 
by coincubation with HDL. Further, we have shown that down-
regulation of the canonical HDL receptor SR-BI inhibits endothe-
lial chylomicron uptake. In vivo, downregulation of SR-BI inhibits 
uptake of DiI-labeled chylomicrons as well as LD accumulation 
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Figure 5. SR-BI deficiency inhibits in vivo aortic EC CM uptake and LD accumulation. WT, iLplfl/fl, and iLpl–/– mice (6–8 per group) were injected with either 
control or SR-BI ASO (100 mg/kg) once a week for 3 weeks. Loss of SR-BI expression was monitored by RT-PCR of liver (A) and aorta (B) as well as by 
immunostaining of aortic EC with SR-BI (D, green; quantified in C). **P < 0.01, Student’s t test. (E–G) DiI-CM (0.5 mg/g TG) was administered retroorbit-
ally to WT mice 72 hours after the last ASO injection. Mice were sacrificed and their aortas harvested 15 minutes after DiI-CM administration, and DiI-CM 
within aortic ECs were visualized by confocal microscope. Treatment with SR-BI ASO induced fasting hypertriglyceridemia (E), and circulating TG levels 
were significantly elevated 15 minutes after DiI-CM injection as compared with mice treated with control ASO (F). SR-BI knockdown significantly inhibited 
DiI-CM uptake in aortic ECs (F, DiI-CM shown in red). White arrows indicate DiI-CM. All comparisons are with control ASO. **P < 0.01; ****P < 0.0001, Stu-
dent’s t test. (H–K) Seventy-two hours after the last ASO injection (H), iLplfl/fl and iLpl–/– mice were fasted overnight and given olive oil by oral gavage (10 
ml/kg). Circulating plasma TG levels (I) and aortic EC LD content (J) were assessed 180 minutes after gavage. As expected, iLpl–/– mice treated with control 
ASO exhibited a significant increase in LD accumulation (K, middle panel) as compared with floxed controls (K, left panel). This phenotype was rescued by 
SR-BI downregulation (K, right panel). Data are represented as mean ± SD. ***P < 0.001; ****P < 0.0001, 1-way ANOVA, Dunnet’s multiple comparisons 
test. Scale bars: 10 μm.
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at least 4.5 mL of liquid was collected with a 1000 μL pipette into a 15 
mL conical tube. PMACs were pelleted by centrifugation (400g for 10 
minutes at 4°C) and resuspended in 1 mL RPMI 1640 culture medium 
(Thermo Fisher Scientific). PMACs were plated in glass coverslips 
at 0.2 × 106 cells/mL in RPMI 1640 culture medium supplemented 
with 10% FBS, 1% penicillin/streptomycin (pen/strep), 10 μM sodium 
pyruvate, 25 mM HEPES, and 100 μM amino acids. PMACs were 
maintained at 37°C and 5% CO2 in a humidified incubator. All experi-
ments were performed within 48 hours after PMAC collection.
Culture of HUVECs. HUVECs were cultured in M199 supple-
mented with EC growth supplement (Yale Vascular Biology and Ther-
apeutics Core Facility), 10% FBS, pen/strep (1:100), and 2.8 mM glu-
tamine and used up to passage 4. For siRNA transfections, HUVECs 
were cultured in EGM-2 media (Lonza) with 5% FBS.
Animals
Three- to four-month-old male WT C57BL/6, Lplfl/fl, iLpl–/–, EC-Cd36fl/fl, 
EC-Cd36–/–, and Ldlr–/– mice were maintained on a 12-hour light/ 12-hour 
dark cycle and given free access to food (laboratory chow diet) and water, 
except for during overnight fasting. Mice were monitored regularly to 
ensure their welfare.
Method details
Oral olive oil gavage and blood sampling. After a 16-hour fast, mice were 
given olive oil by oral gavage at 10 mL/kg (~300 μL). Blood samples 
were drawn at baseline and at 180 and 270 minutes after receiving the 
olive oil gavage. Mice were anesthetized using isoflurane, and blood 
was collected from the retroorbital plexus into heparinized microcap-
illary tubes. Blood was centrifuged at 10,000g for 10 minutes for cell 
removal and collection of the plasma, which was then used immedi-
ately for TG measurements; the rest was frozen at −80°C.
Lipid measurements. Total plasma TG was measured using Infin-
ity Triglyceride Reagent (Thermo Fisher Scientific). NEFA levels 
were measured using a kit (Wako Diagnostics).
ASO treatments. ASO targeting mouse SR-BI was developed and 
provided by Ionis Pharmaceuticals. Mice fasted for 16 hours were 
injected intraperitoneally with control or SR-BI ASO (GCTTCAGT-
CATGACTTCCTT, ISIS no. 353382) at a dose of 100 mg/kg body 
weigh once a week for 3 weeks. Experiments and measurements were 
performed 72 hours after the last ASO injection. SR-BI knockdown 
was assessed by real-time quantitative PCR (qRT-PCR) of samples 
obtained from liver (to assess systemic knockdown) and aortae (to 
assess local knockdown). Three thoracic aortae were pulled per sam-
ple to ensure the collection of sufficient RNA. Additionally, SR-BI 
knockdown in aortic ECs was assessed by en face aorta immunos-
taining using an SR-BI antibody (RRID; catalog AB_2182824).
Tissue gene expression. Total RNA was prepared using a GeneJET 
RNA Purification Kit (Thermo Scientific). One microgram of RNA 
was used for reverse transcription using the Verso cDNA Synthesis 
Kit (Thermo Scientific). qRT-PCR was performed using an ABI 7700 
(Applied Biosystems). Amplification was performed using SYBR Green 
PCR Master Mix (Applied Biosystems). Primers used for PCR amplifi-
cation were obtained from PrimerBank. Analysis was performed using 
Sequence Detection Software (Applied Biosciences). Data were nor-
malized to Rn18s.
En face aorta immunostaining and neutral lipid staining. Mice 
were anesthetized using isoflurane and euthanized by cervical dislo-
Aside from its enzymatic actions, LpL functions as a “bridg-
ing” molecule. By associating with cell surfaces and matrix as well 
as binding lipoproteins, LpL mediates internalization and matrix 
association of lipoprotein lipids (65–68). Very recently, Fischer 
et al. reported that an emulsion created from human TRLs enters 
brown adipose tissue ECs of cold-conditioned mice (69). This 
uptake requires LpL and CD36 and, as for our receptor-mediated 
process, leads to lysosome degradation. It is possible that in 
cold-acclimated mice, LpL anchoring actions are preferentially 
induced, possibly because the high concentrations of FAs gener-
ated inhibit LpL enzymatic activity (70). In contrast, our in vitro 
studies used cultured and aortic ECs lacking LpL and we found 
that aortic EC BODIPY + lipids were greatest in LpL-knockout 
mice, providing evidence for an LpL-independent pathway. In 
our studies, CD36 was not involved in chylomicron uptake by 
cultured ECs and aortic EC uptake of chylomicrons also occurred 
in EC-CD36 knockout. As we showed in the heart (71) and oth-
ers showed in cold-induced brown adipose tissue (72), CD36 is 
needed for optimal uptake of lipids from VLDL but not chylomi-
crons (71, 73). Overall, aortic EC LD content appears to correlate 
with hyperchylomicronemia, occurs in arteries where LpL and its 
binding protein GPIHBP1 are unlikely to be found, and does not 
require cold exposure. Thus, tissue site, lipoprotein size or com-
position, physiologic conditions, and expression of LpL and CD36 
differentiate these 2 pathways for TRL uptake into ECs.
In conclusion, we have defined a pathway for the uptake and 
metabolism of nonlipolyzed chylomicrons (Figure 7). For decades, 
clinicians have questioned how eruptive xanthomas, which are 
found in patients with severe hypertriglyceridemia, could be 
formed if chylomicrons were unable to cross the endothelial bar-
rier. Our data describe a transport of chylomicrons across ECs 
that allows movement of lipids from circulating nascent chylomi-
crons into skin macrophages. This LpL-exclusive pathway likely 
mediates lipid delivery to parenchymal cells, allowing supply of 
needed lipids and fat-soluble vitamins where LpL-dependent 
mechanisms are less abundant.
Methods
Cells
MECs. MECs were obtained from Angiocrine Bioscience. MECs were 
plated in 10 cm tissue-culture dishes precoated with EmbryoMax 
0.1% Gelatin Solution (Sigma Aldrich). Tissue-culture medium was 
DMEM/Ham’s F-12, supplemented with 20% FBS, 1% antibiotic- 
antimycotic, 10 mM HEPES buffer, 1% Glutamax, 5 μM SB 431542, 
50 μg/mL heparin, 20 ng/mL FGF, 10 ng/mL VEGF, and 50 μg/mL 
BT-203 endothelial mitogen (see Supplemental Table 1 for referenc-
es). Cells were maintained in standard tissue-culture conditions (37C, 
5% CO2 in a humidified incubator).
Collection and culture of mouse PMACs. WT C57BL/6J mice were 
given an intraperitoneal injection of zymosan (0.1 mg in 200 μL of 
PBS) to induce mild inflammation. At 72 hours after the injection, mice 
were anesthetized by isoflurane inhalation and euthanized by cervi-
cal dislocation. An incision was performed to expose the peritoneal 
membrane, and 5 mL of ice-cold PBS was injected through the mem-
brane, followed by a gentle massage of the abdomen. Using surgical 
scissors, an incision was performed in the peritoneal membrane, and 
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was incubated with primary antibody (1:500 in 10% BSA) overnight 
with rocking at 4°C, followed by incubation with secondary antibody 
(1:1000 in 10% BSA) for 1.5 hours with rocking at RT. LD staining 
with BODIPY 493/503 was performed by incubation with 1:1000 by 
volume of a BODIPY 493/503 stock solution (5 mM in DMSO) for 30 
minutes at RT. Nuclear staining with DAPI was performed by incuba-
cation. Thoracic aortae were harvested in ice-cold PBS, fixed for 20 
minutes in 10% formalin, and transferred to 12-well plates contain-
ing 0.5 mL of a permeabilizing solution (0.1% Triton X-100 in PBS) 
per well. Aortae were permeabilized for 5 minutes with rocking at 
room temperature (RT), then blocked using BSA (10% in TTBS [TBS 
with 2.5% Tween 20]) for 30 minutes with rocking at RT. Each vessel 
Figure 6. SR-BI deficiency reduces LD content in skin macrophages from iLpl–/– mice. (A) MECs treated with either control or SR-BI ASO were grown to 
confluency in Transwell inserts and deprived of FBS for 24 hours. On the day of the experiment, ECs were either left untreated (control) or exposed to a 
30-minute pulse with chylomicrons, thoroughly washed, and incubated with FBS-free medium with or without atglistatin or BafA1. Inserts were then 
immediately placed into wells containing freshly harvested PMACs and cocultured for 4 hours. PMACs were immunostained for macrophage marker CD68 
(red), and LDs were labeled with BODIPY493/503 (green). (B) Representative images of PMACs following coincubation with ECs treated as indicated. (C) 
LD/cell quantification. PMACs cocultured with ECs exposed to a chylomicron pulse exhibited significantly more LDs than those cocultured with untreated 
ECs. LD accumulation was significantly reduced in PMACs cocultured with ECs treated with BafA1 (but not atglistatin) following the chylomicron pulse. 
SR-BI–deficient ECs exposed to chylomicrons also failed to induce LD biogenesis in cocultured PMACs. Data are represented as mean ± SEM of 5 indepen-
dent experiments. ****P < 0.0001, 1-way ANOVA. (D and E) iLpl–/– mice were injected with either control or SR-BI ASO. Skin samples from the backs of 6 
mice per group, as well as 6 nonhypertriglyceridemic iLplfl/fl controls were immunostained for CD68 (red) and LD staining with BODIPY 493/503 (green). 
Samples were imaged by confocal microscopy (D), and the percentage of CD68/BODIPY 493/503–positive (yellow) macrophages was quantified (>4000 
macrophages per group) (E). LpL deficiency significantly exacerbated LD accumulation in mouse skin macrophages as compared with floxed controls. This 
effect was significantly reduced in iLpl–/– mice treated with SR-BI ASO. Data are represented as mean ± SD. *P < 0.05; ****P < 0.0001 (significantly differ-
ent from Lplfl/fl); ####P < 0.0001 (significantly different from iLpl–/–+ control ASO), 1-way ANOVA, Tukey’s multiple comparisons test. Scale bars: 10 μm.
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Mouse skin macrophage sampling and immunostaining. iLpl–/– mice 
were injected intraperitoneally with control or SR-BI ASO at a dose of 
100 mg/kg body weight once a week for 3 weeks. At 72 hours after 
the last injection, mice (including Lplfl/fl controls) were gavaged with 
olive oil. At 180 minutes after gavage, mice were anesthetized with 
isofluorane and euthanized by cervical dislocation. Hair from the back 
was removed to expose the skin, and a 1 × 1 cm region was excised 
using a sterile blade. Skin samples were immediately overlaid with 
OCT and frozen in liquid nitrogen to preserve sample integrity. OCT 
blocks were subsequently sectioned 3 times at NYU Langone’s Pathol-
ogy Core Facility. Sectioned samples were placed in slides (3 per slide) 
and stored at –80°C for further analysis. Before immunostaining, sam-
ples were placed at RT for 5 minutes, then fixed with 10% formalin for 
20 minutes at RT. Samples were then permeabilized with 0.5% Tri-
ton-X 100 (5 minutes in ice) and blocked with 3% BSA (30 minutes at 
RT). Incubation with CD68 primary antibody (1:300 in 3% BSA) and 
Alexa Fluor secondary antibody (1:400 in 3% BSA) was performed by 
overlaying each skin section with approximately 75 μL of the antibody 
mix, then incubating in the dark for 1 hour at RT. Following incubation 
with antibodies, samples were thoroughly washed with PBS. Final-
ly, each skin section was overlaid with approximately 75 μL BODIPY 
493/503 (1:1000 BODIPY 493/503 stock solution in PBS) to stain 
LDs, and nuclei were highlighted with DAPI (1:10000 DAPI stock 
solution in PBS). A drop of Fluoromount Aqueous Mounting Medium 
(MilliporeSigma) was added to the center of the slide, and a slide glass 
(22 mm × 75 mm) was placed on the skin sections. Skin macrophages 
were imaged by laser scanning confocal microscopy (Leica SP8) with 
an HCX PL APO lambda blue 63×/1.40 oil objective lens at RT. LD- 
containing macrophages were assessed by colocalization of CD68 and 
BODIPY 493/503 signals.
Lipoprotein DiI labeling and isolation. Lipoproteins from human 
or iLpl–/– mouse plasma were isolated by differential density centrifu-
gation. For chylomicron isolation, plasma in a Beckman Coulter tube 
(catalog 344059) was overlaid with an equal volume of 1.006 g/cm3 
density solution and centrifuged at 26,000g in a TH-641 swinging 
bucket rotor (Thermo Scientific) for 45 minutes at 12°C. The chylomi-
cron layer at the top was transferred into an autoclaved 1.5 mL micro-
centrifuge tube using an autoclaved 9-inch Pasteur pipette.
For VLDL isolation, Beckman Coulter tubes containing chylomi-
cron-free plasma and 1.006 g/cm3 density solution were returned to 
the centrifuge and spun at 26,000g for 22 hours at 12°C. The VLDL 
layer at the top was transferred into an autoclaved 1.5 mL microcentri-
fuge tube using an autoclaved 9-inch Pasteur pipette. Following VLDL 
isolation, the rest of the 1.006 g/cm3 density solution was aspirated 
and the remaining plasma overlaid with an equal volume of 1.12 g/
cm3 density solution for LDL isolation. The mix was centrifuged at 
26,000g for 22 hours at 12°C. The LDL layer at the top was transferred 
into an autoclaved 1.5 mL microcentrifuge tube using an autoclaved 
9-inch Pasteur pipette. The remaining top 1.12 g/cm3 density solution 
was aspirated, and the sample was overlaid by an equal volume of 1.34 
g/cm3 density solution for HDL isolation. The mix was centrifuged at 
26,000g for 46 hours at 12°C. The HDL layer at the top was transferred 
into an autoclaved 1.5 mL microcentrifuge tube using an autoclaved 
9-inch Pasteur pipette.
When required, lipoprotein labeling with DiI was performed as 
described by Beigneux et al.(74). Briefly, DiI was dissolved in DMSO 
(3 mg/ml) and 10 μl of this solution was added per 250 μl of human 
tion with 1:5000 by volume of a DAPI stock solution that contained 5 
mg/mL of DAPI in H2O (5 minutes at RT). Stained aortae were placed 
in glass coverslips with the endothelium facing down, and a drop of 
mounting medium was added on top. A slide glass (22 mm × 75 mm) 
was placed on the vessel. Slides covered by 2 clean laboratory wipes 
and 3.5 kg of weight were gently placed above the slides for a maxi-
mum of 5 minutes to flatten the en face aorta sample.
In vivo aortic endothelial uptake of DiI-labeled chylomicrons. Mice 
were fasted overnight, and DiI-chylomicrons (0.5 mg TG/g body 
weight) were injected retroorbitally. Mice were euthanized 15 min-
utes after injection, and thoracic aortas and blood samples were col-
lected for DiI-chylomicron uptake and plasma TG measurements. 
Aortas were fixed with 10% formalin, washed 3 times with PBS, 
and stained with DAPI to highlight nuclei. Laser-scanning confocal 
microscopy (Leica SP8) was used to observe the Dil-chylomicrons 
within aortic ECs. When indicated, newly harvested aortas were 
maintained in FBS-free DMEM for 2 to 30 minutes before fixing to 
assess endothelial DiI-chylomicron signal decline over time.
Macrophage culture with EC-conditioned media. MECs treated 
with either control or SR-BI ASO were cultured in 0.4 μm mem-
brane Transwell inserts and allowed to reach confluency. Before the 
experiment, MECs were switched to FBS-free medium overnight to 
ensure minimal LD content. On the day of the experiment, MECs 
were either left untreated (control) or exposed to a 30-minute pulse 
with purified chylomicrons (4 mg/dL chylomicron TG) in FBS-free 
medium. Following the chylomicron pulse, cells were thoroughly 
washed with PBS and switched to FBS-free medium with or without 
TG hydrolysis inhibitors atglistatin and BafA1. Inserts were then 
immediately placed into 12-well plates containing PMACs cultured 
on glass coverslips and cocultured for 4 hours. PMACs were then 
fixed and immunostained for the macrophage marker CD68, and 
LDs were stained with BODIPY 493/503. Samples were imaged by 
confocal microscopy.
Figure 7. Model. ECs internalize unhydrolyzed chylomicrons via the SR-BI 
receptor. Chylomicrons are then intracellularly hydrolyzed within endo-
thelial lysosomes, and the products of this hydrolysis fuel LD biogenesis. 
Additionally, intracellular chylomicron hydrolysis leads to the release by 
ECs of biologically active factors capable of triggering LD accumulation in 
underlying macrophages.
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um), after which, they were thoroughly washed and incubated with 
FBS-free medium with or without atglistatin (5 μM) or BafA1 (100 
nM). Inserts were then immediately placed into 12-well plates contain-
ing freshly harvested PMACs in glass coverslips and cocultured for 4 
hours. PMACs were fixed and immunostained for macrophage marker 
CD68. LDs were labeled with BODIPY493/503.
UPLC-TOF-MS quantification of FA in conditioned media. MECs 
were maintained in FBS-free media or pulsed with human chylomi-
crons (4 mg/dL TG, 5 replicates per condition) for 30 minutes, then 
thoroughly washed with PBS and switched to FBS-free medium for 
4 hours. Methanol spiked with deuterated lipid standards (Avanti 
Lipids) in a 100 μL per 50 mL concentration was added to conditioned 
media in equal parts. Lipids were extracted using 2× chloroform per 
sample and vortexed for 2 minutes. Samples were then centrifugated 
at 5635g to separate a top polar layer from a bottom nonpolar layer. 
The bottom layer was vacufuged at 30°C to remove chloroform. The 
pelleted dry bottom layer was resuspended in 10 μL of a 4:3:1 ratio of 
isopropanol, acetonitrile, and water. Both the top and the bottom lay-
ers were run in UPLC-TOF-MS with electrospray ionization.
Mobile phase of liquid chromatography was a binary phase con-
sisting of A phase and B phase. A phase consisted of a 5:1:4 ratio of 
isopropanol, methanol, and water with a 5 millimolar ammonium ace-
tate and 0.1% acetic acid buffer. B phase consisted of a 99:1 ratio of 
isopropanol and water with a 5 millimolar ammonium acetate and a 
0.1% acetic acid buffer. The column used for separation was a Zorbax 
Eclipse Plus C18 column with dimensions 4.6mm × 50 mm and 3.5 
micron beads (Agilent). Electrospray temperatures were 300°C, with 
a flow rate of 13 L/min of nitrogen gas running in a positive or neg-
ative charge. A free FA (FFA) standard ladder was created for palmi-
tate, oleate, and linoleate (Sigma-Aldrich). All lipids were dissolved in 
ethanol. FFA standards were calculated and formulated for a starting 
concentration of 100 ng/μL and serially diluted 10× to a final concen-
tration of 0.0 1ng/μL. Standard ladder was processed and run at the 
same time of sample processing.
Image acquisition and analysis. All imaging acquisition was per-
formed at NYU Langone’s Microscopy Core. Samples were imaged by 
laser scanning confocal microscopy (Leica SP8) in the sequential scan 
mode with an HCX PL APO lambda blue 63×/1.40 oil objective lens 
at RT. BODIPY 493/503 particle quantification and size analysis were 
performed using ImageJ (NIH).
Statistics
Statistical analysis was performed using GraphPad Prism 7 software. 
Data are expressed as mean ± SD unless otherwise indicated. Measure-
ments between 2 groups were performed with an unpaired 2-tailed 
Student’s t test. Groups of 3 or more were analyzed by 1-way ANOVA 
with Dunnett’s or Tukey’s post hoc test as indicated. A P value of less 
than 0.05 was considered significant. Statistical parameters for each 
experiment can be found within the corresponding figure legends.
Study approval
All mouse procedures were conducted in conformity with the NIH 
Public Health Service Policy on Humane Care and Use of Laboratory 
Animals and the National Research Council of the National Academy 
of Sciences’ Guide for the Care and Use of Laboratory Animals, and 
were approved by the New York University Langone Medical Center 
Institutional Animal Care and Use Committee.
serum. This mixture was then incubated at 37°C overnight prior to 
lipoprotein isolation. The DiI-labeled chylomicrons were harvested 
and dialyzed against PBS containing 5.0 μM EDTA.
Treatment with chylomicrons in culture. Cells were seeded in glass 
coverslips precoated with 0.1% gelatin and allowed to reach 70% con-
fluency. Before each experiment, cells were deprived of FBS overnight 
to ensure minimal LD occurrence, and all experiments were carried 
out in FBS-free medium. Chylomicrons were added at a concentration 
of 4 mg/dL TG in FBS-free medium. When indicated, cells were pre-
treated with LpL (10 U/mL) for 1 hour at 37°C, then washed 3 times 
with PBS to remove unbound LpL before incubation with chylomi-
crons. For pulse-chase studies, cells were exposed to chylomicrons for 
30 minutes, washed thoroughly with PBS to remove uninternalized 
chylomicrons, and switched to FBS-free medium for 120 minutes. 
For competition studies, DiI-labeled chylomicrons were administered 
in FBS-free medium in the absence or presence of unlabeled VLDL, 
LDL, HDL, or apoB18 at the indicated concentrations. Endocytosis 
inhibitor dynasore (80 μM), ATGL inhibitor atglistatin (5 μM), and 
lysosomal proton pump inhibitor BafA1 (100 nM) were administered 
when required.
In vitro delivery of SR-BI ASO. Mouse heart MECs were seeded in 
0.1% gelatin-precoated 24-well plates (in glass coverslips, for down-
stream imaging studies), or 6-well plates (for Western blot and qRT-
PCR assessment of SR-BI knockdown) and allowed to reach 40% 
confluency. The volumes below are for each well of a 6-well plate and 
could be scaled up or down according to experimental need. Before 
transfection with ASO, culture medium was removed and cells were 
overlaid with 1.8 mL fresh, prewarmed culture medium with FBS. 
Then 5 μl of a 10 μM ASO stock solution was added to 95 μl of FBS-
free DMEM in a sterile 1.5 ml Eppendorf tube, and 4 μl DharmaFECT 
4 was added to 96 μl of DMEM in a separate sterile 1.5 ml Eppendorf 
tube. Both mixtures were combined by adding the DharmaFECT 4 
mixture to the tube containing the ASO, and these were gently mixed 
by tapping the side of the tube. The transfection mixture was incu-
bated at RT for 20 minutes. Cells were removed from the incubator, 
and 200 μl of the ASO/DharmaFECT 4 mix was added to each well 
of the 6-well plate. The mixture was delivered dropwise and evenly 
throughout each well. Cells were allowed to grow for 24 hours, then 
switched to FBS-free medium overnight. Knockdown of SR-BI was 
assessed by qRT-PCR and Western blot.
Immunocytochemistry and neutral lipid staining. Following 
treatment, cells in glass coverslips were washed 3 times with PBS, 
fixed with 10% formalin (20 minutes at RT), permeabilized with 
0.5% Triton-X 100 (5 minutes in ice), and blocked with 3% BSA (30 
minutes at RT). Incubation with primary antibodies (1:300 in 3% 
BSA) was performed overnight at 4°C in a humid chamber. Incuba-
tion with Alexa Fluor secondary antibodies (1:400 in 3% BSA) was 
performed in the dark at RT for 45 minutes in a humid chamber. 
Immunostained coverslips were thoroughly washed with PBS, and 
neutral lipids were stained with BODIPY 493/503 (1:1000 in PBS, 
30 minutes at RT).
Transwell coculture studies. MECs treated with either control or 
SR-BI ASO were cultured in 0.4 μm pore Corning Transwell polyester 
membrane cell culture inserts (MilliporeSigma) for 3 days until they 
reached confluency, then deprived of FBS for 24 hours. On the day of 
the experiment, ECs were either left untreated (control) or exposed to 
a 30-minute pulse with chylomicrons (4 mg/dL TG in FBS-free medi-
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skin samples were sectioned at the NYU Experimental Patholo-
gy Research Laboratory (partially funded by NYUCI Center sup-
port grant NIH/NCI 5 P30CA16087). All confocal microscopy 
experiments were carried out at NYU Langone’s Microscopy 
Laboratory (partially supported by Cancer Center support grant 
P30CA016087 at the Laura and Isaac Perlmutter Cancer Cen-
ter, New York, New York, USA). This study was funded by grants 
HL45095, 73029, and 15328 from the NIH National Heart, Lung, 
and Blood Institute. We thank William S. Blaner for proofreading 
the manuscript and providing helpful comments. Also, we appre-
ciate insights provided by J. Witztum.
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